Uterine fibroids (leiomyomas) affect an estimated 70–80% of women by age 50 and are among the leading indications for hysterectomy worldwide. The mechanisms underlying fibroid development involve a combination of estrogen sensitivity, dysregulated proliferation, and — increasingly recognised — oxidative stress and mitochondrial dysfunction¹¹ oxidative stress and mitochondrial dysfunction
Reactive oxygen species (ROS) promote smooth muscle cell proliferation and extracellular matrix deposition, both hallmarks of fibroid growth. SIRT3 sits at the centre of the mitochondrial antioxidant network, and variants that may alter its expression or activity could modestly shift the threshold for fibroid formation in susceptible women.

SIRT3 (Sirtuin 3) is the principal NAD⁺-dependent protein deacetylase²² NAD⁺-dependent protein deacetylase
SIRT3 removes acetyl groups from lysine residues on mitochondrial proteins, activating enzymes involved in energy metabolism and antioxidant defence inside mitochondria. Its major substrates include MnSOD2 (the primary mitochondrial superoxide scavenger), IDH2 (which regenerates the NADPH needed to recycle glutathione), and complexes of the electron transport chain. When SIRT3 activity is adequate, mitochondrial ROS remain controlled; when SIRT3 is reduced, ROS accumulate and can drive cell proliferation and fibrosis — two defining features of fibroid growth.

The Mechanism

rs547025 is located in intron 6 of SIRT3 on chromosome 11p15.5, within a gene region that contains a characterised enhancer variable-number tandem repeat (VNTR) in intron 5. While rs547025 itself sits approximately 128 bp into the intron adjacent to exon 3 in some transcripts (HGVS: c.280+128A>G on the coding strand), the broader SIRT3 locus contains regulatory elements capable of allele-specific variation in transcriptional efficiency. The intronic location and the protective signal of the C allele are consistent with a regulatory mechanism in which different alleles at or near rs547025 alter the binding affinity of transcription factors — potentially GATA2 or AP-1 family members that have been shown to act on the nearby SIRT3 intron-5 VNTR enhancer — thereby modulating SIRT3 expression levels³³ modulating SIRT3 expression levels
The intron-5 VNTR of SIRT3 has allele-specific enhancer activity demonstrated in transfection experiments; alleles lacking enhancer repeat units show reduced SIRT3 transcription.

The link to fibroid tissue is directly supported by protein-expression data: normal myometrial tissue expresses substantially higher SIRT3 protein than matched uterine fibroid tissue in the same women. When SIRT3 is activated pharmacologically in human leiomyoma (HuLM) cells, proliferation and collagen deposition are selectively suppressed, while normal uterine smooth muscle (UTSM) cells are unaffected — indicating that lower SIRT3 expression is a feature of, and may contribute to, the fibroid phenotype⁴⁴ lower SIRT3 expression is a feature of, and may contribute to, the fibroid phenotype
Conference abstract, Fertility & Sterility 2020: honokiol (a SIRT3 activator) inhibits HuLM leiomyoma cell growth selectively while UTSM cells resist treatment at all tested doses.

A parallel line of evidence comes from the myometrium during parturition: SIRT3 expression falls sharply in term laboring myometrium relative to non-laboring myometrium, and SIRT3 knockdown in primary myometrial cells amplifies NF-κB signalling, driving production of pro-inflammatory cytokines (IL-6, CXCL8), prostaglandins (via PTGS2), and matrix metalloproteinases. The same NF-κB and ROS-driven inflammatory programme is implicated in fibroid growth⁵⁵ is implicated in fibroid growth
Lim et al. 2016, Biology of Reproduction.

The Evidence

The primary evidence linking rs547025 specifically to fibroid risk comes from a case-control study of 737 Central Russian women with ultrasound-confirmed uterine fibroids and 451 controls⁶⁶ case-control study of 737 Central Russian women with ultrasound-confirmed uterine fibroids and 451 controls
Ponomareva, Kobzeva, Bushueva et al. Front Biosci (Schol Ed), 2024. PMID 39736018. Probe-based PCR was used to genotype seven GWAS-significant SNPs. The C allele of rs547025 was associated with a statistically significant reduction in fibroid risk in the overall cohort (OR = 0.61, 95% CI 0.43–0.87, p = 0.005), placing it among the strongest single-locus protective associations in the panel. Subgroup analyses revealed that protection was most pronounced in women with normal fruit and vegetable intake (OR = 0.39, 95% CI 0.21–0.75, p = 0.002), no prior spontaneous abortions (OR = 0.48, 95% CI 0.33–0.70, p = 0.0001), and no prior pelvic inflammatory disease (OR = 0.55, 95% CI 0.38–0.80, p = 0.002), pointing to gene-environment interactions in which co-existing oxidative burden may attenuate the protective effect.

The broader SIRT3 locus at 11p15.5 has independently appeared in uterine fibroid GWAS datasets, and rs73392700 — an intronic SIRT3 variant identified in a multi-ancestry GWAS — showed an OR of 0.77 (95% CI 0.74–0.79, p = 1.09 × 10⁻⁵⁰) in East Asian and Central/South Asian ancestry analyses, confirming that protective variation in the SIRT3 locus for fibroids is not restricted to one population.

The evidence at the specific rs547025 locus is based on a single case-control study from a Central Russian population and has not yet been independently replicated; the evidence level is therefore rated moderate. The biological rationale is plausible and supported by functional data from fibroid tissue expression studies, but replication in independent cohorts is needed before clinical utility can be established.

Practical Implications

Carrying two copies of the common T allele (TT) removes the modest protection associated with the C allele. This does not meaningfully change population-level fibroid risk on its own — the absolute difference conferred by a single variant of this effect size is small — but it may be relevant when considered alongside other fibroid risk factors: African ancestry, nulliparity, obesity, early menarche, vitamin D deficiency, and family history.

SIRT3's primary substrate pathway (NAD⁺ → SIRT3 → MnSOD2/IDH2 → glutathione regeneration) is nutritionally modifiable: SIRT3 requires NAD⁺ as a cofactor, and NAD⁺ declines with age and metabolic stress⁷⁷ NAD⁺ declines with age and metabolic stress
The SIRT3/NAD⁺ axis is a recognised mechanism for age-related mitochondrial dysfunction and a target of active supplementation research | Weir et al. 2013. Maintaining adequate NAD⁺ precursor intake (via dietary sources or supplementation) may partially compensate for reduced SIRT3 activity in TT carriers, though direct evidence specific to fibroid outcomes is not yet available.

Interactions

rs7986407 (FOXO1, 13q14.11): FOXO1 is a decidualization marker downstream of estrogen receptor signalling, and the rs7986407 locus reached genome-wide significance for fibroid risk (OR ≈ 1.09, p = 1.2 × 10⁻¹¹) in UK Biobank GWAS. Both rs547025 (SIRT3) and rs7986407 (FOXO1) were included in the Ponomareva 2024 panel. SIRT3 and FOXO1 operate on converging pathways: SIRT3 deacetylates and activates FOXO3a (a related FOXO family member), which in turn upregulates MnSOD2. FOXO1 similarly controls oxidative stress gene expression in uterine stroma. Women carrying both the SIRT3 T allele (reduced mitochondrial antioxidant protection) and a risk allele at rs7986407 (disrupted FOXO1-driven decidualization and redox control) may experience additive impairment of the dual mitochondrial-nuclear antioxidant axis in uterine tissue.

Compound action proposal for supervisor: women carrying TT at rs547025 (SIRT3) and who also carry a risk allele at rs7986407 (FOXO1, 13q14.11) may have additive impairment of mitochondrial and FOXO-driven antioxidant defence in uterine smooth muscle. The combined recommendation would be enhanced monitoring for fibroid development (annual pelvic ultrasound from age 30 in symptomatic women) and targeted optimisation of the NAD⁺/SIRT3 axis (NAD⁺ precursor supplementation at evidence-supported dosages). Evidence level: emerging (pathway convergence, single association study, no formal published gene-gene interaction analysis for this specific pair).

Every immune response needs a brake. T-cell protein tyrosine phosphatase — known as TC-PTP, encoded by PTPN2 — is one of the body's primary molecular brakes on the JAK-STAT signaling cascade¹¹ JAK-STAT signaling cascade
Janus kinase–signal transducer and activator of transcription: a core cytokine signaling pathway that controls immune cell proliferation, differentiation, and inflammation. The rs559406 variant is an intronic SNP in the PTPN2 gene on chromosome 18. Its G allele — the reference allele in the human genome — is associated with subtly reduced TC-PTP function, amplified cytokine signaling, and increased susceptibility to psoriasis and related inflammatory conditions. The T allele confers lower risk.

The Mechanism

TC-PTP removes activating phosphate groups from JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5 — the very proteins that translate cytokine receptor signals into inflammatory gene transcription. When TC-PTP activity is reduced, these kinases and transcription factors remain phosphorylated longer, sustaining inflammatory responses well past the point where they should resolve. In T cells specifically, this translates to enhanced Th1 differentiation, expanded cytotoxic CD8+ responses, and impaired regulatory T-cell (Treg) maintenance — three converging forces toward autoimmunity.

The intronic location of rs559406 suggests it influences PTPN2 expression or mRNA splicing rather than protein structure directly, a pattern consistent with other PTPN2 variants in strong linkage disequilibrium at this locus (including rs1893217²² rs1893217
An intronic PTPN2 variant in perfect LD with rs2542151, the primary IBD susceptibility SNP at this locus; same gene region, different LD block from rs559406). The specific functional consequence of the rs559406 G allele at the molecular level has not yet been characterized in published studies; the risk designation rests on genome-wide association data.

The Evidence

A genome-wide association study from the VA Million Veteran Program — one of the largest genetic studies ever conducted (>635,000 participants) — identified rs559406-G as a genome-wide significant risk allele for psoriasis³³ identified rs559406-G as a genome-wide significant risk allele for psoriasis
GCST90476186/90476190; G allele beta ≈0.073, p ≈1×10⁻¹¹; ~16,700 psoriasis cases vs ~430,000 controls, European ancestry. The modest beta coefficient (≈0.073 on a log-odds scale) corresponds to an odds ratio of approximately 1.08 per G allele — a small but population-relevant effect.

Functional studies at the gene level help explain why PTPN2 variants influence autoimmune disease. In a mouse model of type 1 diabetes, T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome⁴⁴ T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome
Mice lacking PTPN2 only in T cells showed substantially higher T1D incidence; CD8+ T-cell PTPN2 loss alone was sufficient to drive beta-cell destruction. In human pancreatic beta cells, silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%⁵⁵ silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%
Mechanism: increased JNK1 and BIM phosphorylation drives apoptosis; blocking JNK1 or BIM restored survival, identifying beta-cell protection as a direct function of TC-PTP activity. In intestinal epithelial cells, the CD-associated PTPN2 variant rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion⁶⁶ rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion
Impaired muramyl-dipeptide-induced autophagy in both intestinal epithelial cells and monocytes carrying the risk genotype, demonstrating how a slight reduction in phosphatase activity can tip the immune balance toward chronic inflammation.

At the clinical level, PTPN2 variants at this locus predict response to targeted therapies. The closely related intronic variant rs1893217 (in the same gene region, in linkage disequilibrium with rs2542151) showed that in the Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)⁷⁷ Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)
Significant association between PTPN2 C-allele carrier status and anti-TNF treatment success in both CD and UC. A separate study found that the PTPN2 rs7234029 risk allele was associated with substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease⁸⁸ substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease
89.9% nonresponse in risk allele carriers vs 67.6% in non-carriers (p=0.005), illustrating how PTPN2 genotype can guide biologic selection.

Practical Actions

Carrying the rs559406 G allele — particularly two copies — reflects a JAK-STAT signaling system that runs slightly hotter than average. The clinical consequence depends heavily on cumulative immune burden: other genetic risk factors, infection history, microbiome composition, and environmental stressors all interact with this baseline. For people who already have psoriasis or another autoimmune condition associated with JAK-STAT overactivation, the PTPN2 variant has actionable pharmacogenomic implications — JAK inhibitors (tofacitinib, upadacitinib, baricitinib) target the exact pathway that TC-PTP normally dampens, and preliminary evidence suggests PTPN2 risk carriers may have heightened responsiveness to these therapies.

For people with inflammatory bowel disease, PTPN2 genotype at this locus appears to predict biologic response patterns that can guide prescribing — though the evidence is currently at the literature/gene-association level, not formal CPIC/DPWG guideline status.

Interactions

PTPN2 functions synergistically with PTPN22 (rs2476601, R620W), which encodes a related phosphatase active in lymphocyte receptor signaling. Both genes act as negative regulators of T-cell activation — PTPN2 through JAK-STAT, PTPN22 through TCR signaling — and carrying risk variants in both simultaneously creates a broader impairment of immune braking. Reviews of PTPN2/PTPN22 combined risk have noted additive effects on T1D and IBD susceptibility, suggesting that evaluating both variants together provides a more complete picture of autoimmune risk than either alone.

Intronic PTPN2 variants at this locus may also interact with JAK-pathway modifying variants in cytokine receptor genes (IL2RA, IL7R, IL21R). The IBD literature has documented epistasis between PTPN2 rs2542151 and autophagy gene ATG16L1 rs2241879 (p=0.024), suggesting convergent effects on mucosal homeostasis when both pathways are impaired.

The TNFAIP3 gene at chromosome 6q23.3 encodes A20, the central negative regulator of NF-κB inflammatory signaling. Multiple independent genetic signals cluster at this locus, each tagging different disease susceptibilities and haplotypes — but not all signals confer the same risks. rs610604, an intronic variant sitting inside TNFAIP3 itself (rather than in the upstream intergenic region), marks the primary psoriasis susceptibility haplotype¹¹ primary psoriasis susceptibility haplotype
Nair et al. 2009 identified rs610604 as the most significant TNFAIP3 signal for psoriasis in a genome-wide scan of 1,409 psoriasis cases and 1,436 controls, followed up in 5,048 cases and 5,041 controls at this locus. Critically, this psoriasis haplotype is genetically distinct from the rheumatoid arthritis and lupus signals at the same locus — a finding with direct clinical implications.

The Mechanism

rs610604 sits in intron 6 of TNFAIP3 and does not alter the A20 protein sequence. Its biological effect is regulatory: RegulomeDB annotation²² RegulomeDB annotation
RegulomeDB scores transcription factor binding evidence and chromatin accessibility; score 4 indicates TF binding plus DNase hypersensitivity, consistent with an active regulatory region assigns this variant a score of 4, indicating evidence of transcription factor binding plus open chromatin — the molecular signature of a functional intronic regulatory element. The G allele of rs610604 likely modulates TNFAIP3 expression in keratinocytes or skin-resident immune cells in a tissue-specific manner, in contrast to the upstream regulatory variants rs6920220 and rs10499194 that primarily affect A20 levels in synovial and hematopoietic cells.

A20 functions as a dual ubiquitin-editing enzyme³³ dual ubiquitin-editing enzyme
A20 has both deubiquitinase (OTU domain) and E3 ubiquitin ligase (zinc finger domain) activities, enabling it to simultaneously remove activating ubiquitin chains from RIP1 and attach inhibitory chains to TRAF6, shutting down NF-κB signaling through two independent enzymatic steps. When A20 regulatory function is perturbed in skin tissue, NF-κB-driven cytokine production persists, promoting the Th17/IL-23 inflammatory axis characteristic of psoriasis rather than the anti-citrullinated protein antibody-driven response typical of RA.

The Evidence

The Nair et al. 2009 genome-wide scan⁴⁴ Nair et al. 2009 genome-wide scan
Published in Nature Genetics, February 2009 identified rs610604 as the lead TNFAIP3 signal for psoriasis (P=9×10⁻¹², OR=1.19), confirming TNFAIP3 alongside TNIP1 as the NF-κB pathway susceptibility locus for psoriasis. Both genes act downstream of TNF-α in the same negative-feedback loop, explaining why psoriasis — a disease driven by TNF-α and NF-κB activity in skin — is sensitive to genetic variation at this locus.

A meta-analysis of 13 case-control studies⁵⁵ meta-analysis of 13 case-control studies
13,908 psoriasis cases and 20,051 controls across European, Asian (Chinese, Indian, Pakistani), African (Egyptian), and American cohorts confirmed the association: G vs T OR=1.19 (95% CI 1.09–1.31, P=0.0002). The association holds across ancestry groups, though the G allele frequency varies substantially — common in African populations (~63%), intermediate in European (~33%) and South Asian (~32%) populations, and rare in East Asians (~8%). This pattern means the locus contributes differentially to psoriasis risk burden across populations.

A key insight from meta-analysis of the TNFAIP3 region in five European psoriasis cohorts⁶⁶ meta-analysis of the TNFAIP3 region in five European psoriasis cohorts
4,704 cases and 7,805 controls from UK, Swedish, and other European ancestry cohorts is that the psoriasis risk haplotype is categorically distinct from the autoimmune haplotypes associated with RA, SLE, and systemic sclerosis at the same locus. Haplotypes that are risk-conferring in SLE are actually protective in psoriasis, and vice versa. This means carrying the rs6920220 A allele (RA/SLE risk) does not compound psoriasis risk from rs610604 — these are independent signals marking different disease pathways through the same gene.

Practical Actions

The G allele at rs610604 confers modest but replicated psoriasis susceptibility (OR ~1.19 per allele). For GT and GG carriers who have or develop psoriasis, the most clinically actionable finding is the TNF inhibitor response prediction⁷⁷ TNF inhibitor response prediction
Michigan cohort of 432 psoriasis patients: GG genotype had 90.7% good response to etanercept vs 70.3% for TT; meta-analysis OR=1.64 for etanercept, OR=1.50 for all TNF blockers combined. G allele carriers are substantially more likely to respond well to etanercept and other TNF inhibitors — information worth sharing with a dermatologist before biologic selection.

For carriers without active psoriasis, the variant indicates modestly elevated NF-κB inflammatory tone in skin. Minimizing known psoriasis triggers — Koebner phenomenon (skin trauma), streptococcal infections, rapid withdrawal of systemic corticosteroids, certain medications (lithium, beta-blockers, antimalarials) — is particularly relevant. Maintaining serum 25(OH)D above 40 ng/mL supports skin barrier function and immune regulation; the VITAL trial⁸⁸ the VITAL trial
25,871 participants; vitamin D 2,000 IU/day reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) provides the strongest randomized evidence for vitamin D's anti-inflammatory benefit in autoimmune-susceptible individuals.

Interactions

rs610604 tags a psoriasis-specific haplotype that is genetically and functionally distinct from the other TNFAIP3 variants in this database. The RA and SLE risk signals — rs6920220 (upstream regulatory, reduces A20 expression) and rs2230926 (F127C missense, impairs A20 enzymatic activity) — operate through different mechanisms and their risk haplotypes are not concordant with the psoriasis haplotype. Carrying risk alleles at both rs6920220 and rs610604 does not represent straightforward compound risk; the two signals may actually tag opposing haplotypes.

TNIP1 (encoded by TNIP1, also called ABIN-1) works directly with A20 in the same NF-κB feedback pathway: A20 recruits TNIP1 as a scaffolding partner to terminate NF-κB signaling. The TNIP1 variant rs17728338 is also a psoriasis susceptibility SNP — identified in the same Nair 2009 GWAS — and rs610604 G carriers who also carry the rs17728338 risk allele may face compounded psoriasis risk through dual impairment of the A20-TNIP1 complex.

The IL23A locus variant rs2066808 represents the parallel IL-23 pathway susceptibility in psoriasis. Both the NF-κB pathway (TNFAIP3/TNIP1) and the IL-23 signaling axis (IL23A/IL23R/IL12B) converge on Th17 cell activation in psoriatic skin lesions.

Von Willebrand factor is the molecular bridge between injury and clot. When a blood vessel tears, VWF multimers¹¹ VWF multimers
Giant protein complexes assembled in endothelial cells and megakaryocytes; circulating forms are anchored to collagen at the injury site unspooling from the vessel wall snag passing platelets, holding them in place until a stable clot forms. Without enough VWF, platelets arrive but can't stick — and minor cuts, dental procedures, or surgery become sources of prolonged, difficult-to-stop bleeding. The c.4944del variant deletes a single adenine from the VWF coding sequence, shifting the reading frame at codon 1649 and generating a premature stop signal that destroys a large portion of the mature protein.

The Mechanism

VWF spans 53 exons²² 53 exons
VWF is one of the largest genes in the genome at ~178 kb on chromosome 12p13 (gene located on the minus strand). The c.4944del deletion falls in exon 28 of the canonical transcript (NM_000552.5), removing one adenine at coding position 4944 and creating a p.Ile1649fs frameshift. This disrupts the downstream D4 and C domains of the VWF preproprotein — regions critical for multimerisation and platelet GPIbα binding.

A key finding from functional studies is that the aberrant mRNA remains stable³³ the aberrant mRNA remains stable
Mohlke et al. 1996 (PMID 8857958) showed mRNA from the deleted allele is not degraded by nonsense-mediated decay, unlike many other frameshift alleles rather than being cleared by nonsense-mediated decay. The truncated protein is synthesised but retained within the endoplasmic reticulum — it cannot undergo normal propeptide processing or multimerisation, and is therefore not secreted. Critically, the truncated VWF does not exert a dominant-negative effect on protein from the intact allele: wild-type VWF from the normal chromosome can still assemble and be secreted normally. This means the disease mechanism is purely quantitative (haploinsufficiency) — the cell produces only half as much functional VWF as normal. The result in heterozygotes is reduced circulating VWF levels (typically 20–50% of the normal range), the hallmark of type 1 von Willebrand disease.

In the rare homozygous state, no functional VWF is produced at all, collapsing VWF levels to near zero and producing the severe bleeding phenotype of type 3 VWD⁴⁴ type 3 VWD
Type 3 VWD has an estimated prevalence of 1–3 per million; heterozygous parents of type 3 children are typically asymptomatic or have mild type 1.

The Evidence

This frameshift mutation (or close variants in the same exon) has been identified repeatedly across Northern European populations with VWD type 3. Schneppenheim and colleagues⁵⁵ Schneppenheim and colleagues
Schneppenheim R et al., Hum Genet, 1994 identified a deltaC mutation in VWF exon 18 as "the most common molecular defect in German patients with VWD type III," detecting it in five unrelated families with distinct haplotypes — pointing to recurrent de novo mutation rather than a single ancestral founder.

A follow-up functional study by Mohlke and colleagues⁶⁶ Mohlke and colleagues
Mohlke KL et al., Br J Haematol, 1996 confirmed the mechanistic picture: the frameshift allele produces stable mRNA but misfolded protein that is retained and degraded intracellularly. Because the truncated protein does not interact with wild-type VWF, heterozygous carriers experience simple haploinsufficiency — reduced synthesis, not a structurally abnormal multimer pattern. This is important clinically: it means the bleeding phenotype in heterozygotes is driven entirely by VWF quantity, and therapeutic approaches that raise VWF levels (desmopressin, VWF concentrate) are appropriate.

Atiq et al. 2022⁷⁷ Atiq et al. 2022
A study of 390 well-characterised Dutch VWD patients in the WiN cohort confirmed that VWF frameshift and nonsense variants in type 1 VWD patients produce disease through reduced synthesis/secretion rather than the accelerated clearance mechanism seen in most missense variants. Type 1 patients with molecular-confirmed VWF variants show "clearly distinct" clinical features — earlier diagnosis, lower VWF antigen levels, and more pronounced bleeding symptoms — compared to type 1 patients without a detected VWF variant.

Practical Implications

For heterozygous carriers, the central clinical question is whether circulating VWF levels are sufficiently reduced to cause clinically relevant bleeding. VWF levels vary substantially even among carriers of the same mutation, influenced by blood type (O blood type reduces VWF levels by ~25%), age, and other modifiers. Confirming VWF antigen level, VWF activity (ristocetin cofactor assay), and factor VIII level provides the quantitative foundation for clinical management. Most heterozygotes will have VWF levels in the 30–60% range (normal 50–200%), placing them in the type 1 or low-VWF category. Bleeding symptoms in this range are primarily mucocutaneous — nosebleeds, easy bruising, heavy menstrual bleeding, and prolonged bleeding after dental extractions or surgery.

Desmopressin (DDAVP) is the first-line treatment for most type 1 VWD patients with this haploinsufficiency mechanism: it triggers endothelial cells to release stored VWF from Weibel-Palade bodies, temporarily raising plasma VWF 2–4 fold. A formal desmopressin challenge test at a haemostasis centre establishes individual responsiveness and the duration of effect before any elective procedure.

Interactions

The c.4944del frameshift interacts with [ABO blood group | O blood type reduces VWF antigen levels by approximately 25% compared to non-O blood types through altered VWF glycosylation and increased clearance] — carriers with blood type O may have VWF levels that fall below the 30% diagnostic threshold for type 1 VWD even if they are mildly symptomatic. Conversely, blood type A, B, or AB can partially compensate for the haploinsufficiency, keeping measured VWF levels in a borderline range despite the same genotype. This VWF × ABO interaction is why VWF level measurement and bleeding history together — rather than genotype alone — drive management decisions.

Women with this variant face compounded risk during menstruation, pregnancy, and delivery. VWF levels rise naturally during pregnancy (sometimes normalising in heterozygotes) but fall rapidly postpartum, creating a window of heightened bleeding risk in the hours after delivery.

TACI (Transmembrane Activator and CAML Interactor) is a receptor on B cells that functions as a critical switch for antibody class switching and the production of T-independent antibody responses. When TACI binds its natural ligands — BAFF and APRIL¹¹ BAFF and APRIL
B-cell Activating Factor and A Proliferation-Inducing Ligand, both members of the TNF superfamily expressed by innate immune cells; BAFF is also called BLyS (B Lymphocyte Stimulator) — it activates NF-κB signaling inside B cells, driving them to switch from producing IgM to producing IgG and IgA. The A181E variant (rs72553883) introduces a glutamic acid in place of alanine at position 181, disrupting the transmembrane domain of the protein where this intracellular signaling is coordinated. The result is a TACI receptor that can bind its ligands but cannot relay the activation signal — leaving B cells unable to mount normal class-switching responses.

The Mechanism

Unlike the related C104R variant²² C104R variant
rs34557412 (p.Cys104Arg) — a different TNFRSF13B mutation that disrupts ligand binding itself, found in 4–5% of CVID patients; A181E and C104R together account for over 90% of CVID-associated TNFRSF13B variants, the A181E protein reaches the B-cell surface and binds BAFF and APRIL normally. The problem lies downstream: the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation³³ the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation
Fluorescence resonance energy transfer studies show impaired intracellular domain clustering; NF-κB response to APRIL stimulation is undetectable in cells expressing A181E vs. dose-dependent response in wildtype. This impairs the intracellular clustering of TACI's cytoplasmic domain that normally assembles signaling complexes with CAML and TRAF6.

Heterozygous carriers of A181E show elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells⁴⁴ elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells
These autoreactive B cells are normally culled in the bone marrow through central tolerance; A181E heterozygotes show elevated polyreactive and ANA-positive B cells at a stage where wildtype TACI hemizygotes do not — suggesting A181E protein exerts dominant-negative effects on wildtype TACI, which is not seen in individuals who simply lack one functional TACI copy (hemizygotes). This distinction suggests that the A181E protein actively interferes with normal TACI function rather than merely reducing its quantity — making the mechanism closer to dominant-negative than to simple haploinsufficiency.

The Evidence

The founding study by Castigli et al. (2005)⁵⁵ Castigli et al. (2005)
First demonstration of TNFRSF13B mutations in CVID; B cells from carriers failed to produce IgG or IgA after APRIL stimulation despite normal surface TACI expression established that TACI mutations prevent B cells from producing IgG and IgA in response to APRIL, even when surface receptor expression and ligand binding appear intact. Among 564 patients with antibody deficiency, A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)⁶⁶ A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)
C104R showed stronger enrichment: 26 patients (4.6%) vs 6 controls (0.9%), P<0.001; A181E enrichment was not statistically significant in this specific cohort. A larger meta-analysis of 1,439 CVID patients and 3,558 controls found A181E significantly enriched in patients (OR 5.60, 95% CI 2.99–10.51) when examining well-characterized cohorts.

Murine studies with the A181E equivalent mutation A144E⁷⁷ A181E equivalent mutation A144E
Human position 181 = murine position 144; the transmembrane domain is structurally conserved; the A144E mutation in mice reproduces the human A181E biochemical phenotype including impaired NF-κB activation confirmed that transgenic mice carrying this mutation had significantly reduced serum IgA levels, impaired IgG1 responses to polysaccharide antigens, and reduced B-cell proliferation in response to APRIL — closely mirroring what is observed in human A181E carriers.

Clinical data show that heterozygous carriers present across a spectrum: from fully healthy individuals to those with selective IgA deficiency, to overt CVID with recurrent sinopulmonary infections. The index case in the original TACI/A181E literature presented with recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis⁸⁸ recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis
Classic pattern of T-independent antibody deficiency: encapsulated bacteria (H. influenzae, Streptococcus pneumoniae) that normally require polysaccharide-specific IgA and IgG2 for mucosal clearance. A key clinical nuance: monoallelic (heterozygous) A181E carriers show higher rates of autoimmune manifestations — particularly thrombocytopenia and lymphoproliferation — compared to biallelic carriers, who tend toward pure antibody deficiency with paradoxically lower autoimmunity rates.

Practical Implications

The A181E variant is rare globally (approximately 0.5% allele frequency) but clinically significant when present. Most heterozygous carriers have near-normal immunoglobulin levels and no obvious immunodeficiency. The variant functions as a susceptibility allele that requires additional genetic or environmental cofactors to manifest as overt disease. However, a subset of carriers — particularly those with concurrent infections, autoimmune triggers, or additional immune-related variants — may develop measurable immune dysfunction.

Monitoring serum IgG, IgA, and IgM levels provides the most direct readout of TACI function. IgA is particularly sensitive, since TACI-dependent class switching to IgA at mucosal surfaces is a key APRIL-driven function. Vaccination response testing with unconjugated pneumococcal polysaccharide (PPV23) — which activates T-independent IgG2/IgA responses through the same pathway TACI controls — provides a functional measure of whether the variant is causing clinically meaningful B-cell impairment.

Interactions

A181E interacts with the related C104R variant (rs34557412) in compound heterozygosity. Compound A181E/C104R heterozygotes show a more penetrant antibody deficiency phenotype than simple monoallelic carriers. Among patients with biallelic mutations (including compound heterozygotes), the clinical picture typically consists of pure hypogammaglobulinemia with relatively lower autoimmunity burden, while monoallelic A181E carriers show paradoxically higher rates of autoimmune manifestations including thrombocytopenia and lymphoproliferation. This distinction has been attributed to the dominant-negative mechanism of A181E, which — even in the heterozygous state — disrupts wildtype TACI's role in central B-cell tolerance.

Estrogen doesn't come only from the ovaries. After menopause — and throughout life in men and premenopausal women — a substantial fraction of circulating estradiol is made locally in adipose tissue, bone, brain, and liver through the action of aromatase¹¹ aromatase
the enzyme encoded by CYP19A1 that converts androgens such as testosterone and androstenedione into estrogens. The amount of aromatase produced in peripheral tissues is controlled partly by which alleles you carry at regulatory sites within CYP19A1. rs727479, a variant in intron 4 of the gene, has emerged through multiple independent genome-wide association studies as the single best common genetic predictor of circulating estradiol levels — particularly in postmenopausal women, when peripheral aromatase becomes the dominant source of estrogen.

The Mechanism

rs727479 is located at chr15:51242349 (GRCh38), within an intron of CYP19A1 on the minus strand of chromosome 15. It does not alter the aromatase protein sequence; instead, it influences gene expression. Glubb et al. demonstrated that the variant alters binding motifs for four transcription factors and lies within a putative regulatory element²² Glubb et al. demonstrated that the variant alters binding motifs for four transcription factors and lies within a putative regulatory element
Glubb DM et al. The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome. Front Pharmacol 2017, providing a direct mechanistic explanation for why C-allele carriers produce less aromatase mRNA in peripheral tissues. Because CYP19A1 is regulated by tissue-specific promoters, the effect is most pronounced in tissues that rely on intronic regulatory elements — including adipose and bone — where aromatase expression in postmenopausal women accounts for the majority of total-body estrogen synthesis.

The C allele at this position is the minor allele globally (~29%), with the common A allele carried by ~71% of people. In genome files, alleles are reported on the plus strand: A is the common allele associated with normal aromatase expression, and C is the minor allele associated with lower expression and lower estradiol.

The Evidence

Circulating estradiol. Prescott et al. conducted a genome-wide association study in ~1,600 postmenopausal women not using hormone therapy³³ Prescott et al. conducted a genome-wide association study in ~1,600 postmenopausal women not using hormone therapy
Prescott J et al. Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women. PLoS One 2012. rs727479 was the top signal at the CYP19A1 locus for circulating estradiol (β = −0.107, p = 5.11×10⁻⁷), with 34 additional correlated SNPs in the region reaching p < 10⁻⁵. Glubb et al. subsequently synthesized data across four large studies totalling more than 10,000 women⁴⁴ Glubb et al. subsequently synthesized data across four large studies totalling more than 10,000 women
Glubb DM et al. Front Pharmacol 2017 and identified rs727479 as the variant that best captures the estradiol signal across the locus, with effect sizes of 5–10.7% lower estradiol per C allele (p = 1.3×10⁻¹⁰ in the largest dataset). All other associated CYP19A1 variants were in linkage disequilibrium with rs727479 (r² = 0.10–0.51), confirming a single genetic signal.

Bone mineral density. Estradiol is a key suppressor of osteoclast-driven bone resorption. Eriksson et al. used Mendelian randomization in 11,097 men to establish a causal link between CYP19A1-driven circulating estradiol and lumbar spine bone mineral density⁵⁵ Eriksson et al. used Mendelian randomization in 11,097 men to establish a causal link between CYP19A1-driven circulating estradiol and lumbar spine bone mineral density
Ruth KS et al. Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men. J Clin Endocrinol Metab 2018: each 1 pg/mL genetically higher estradiol was associated with a 0.048 SD increase in lumbar spine BMD. This finding is consistent with the known biology of estrogen deficiency and osteoporosis, and extends it to genetic variation in estrogen biosynthesis.

Endometrial cancer. Thompson et al. fine-mapped the CYP19A1 locus and applied Mendelian randomization to establish that the estradiol-raising allele causally increases endometrial cancer risk⁶⁶ Thompson et al. fine-mapped the CYP19A1 locus and applied Mendelian randomization to establish that the estradiol-raising allele causally increases endometrial cancer risk
Thompson DJ et al. CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 2016. rs727479 was among the lead variants at the locus; the C allele (lower estradiol) corresponds to lower endometrial cancer risk.

Late-life depression. Ancelin et al. followed 1,007 adults aged 65 or older and found that CYP19A1 estradiol-modulating variants were associated with depression risk in a sex-specific pattern⁷⁷ Ancelin et al. followed 1,007 adults aged 65 or older and found that CYP19A1 estradiol-modulating variants were associated with depression risk in a sex-specific pattern
Ancelin ML et al. Aromatase (CYP19A1) gene variants, sex steroid levels, and late-life depression. Depress Anxiety 2020. In postmenopausal women without prior depression, lower-estradiol genotypes increased incident depression risk; in women with prior depression, some variants were protective. This reflects the known role of estrogen in modulating serotonergic and noradrenergic neurotransmitter systems.

Aromatase inhibitor response. Because rs727479 predicts baseline aromatase output, individuals with higher baseline aromatase expression (AA genotype) require more complete suppression to achieve the same absolute estradiol reduction during aromatase inhibitor therapy. The clinical significance for treatment outcomes remains an active area of investigation.

Practical Actions

Carriers of the CC genotype produce meaningfully less estrogen through peripheral aromatase. In postmenopausal women, this translates to clinically lower serum estradiol, which has downstream effects on bone density, cardiovascular risk, mood, and endometrial cancer risk (reduced in CC carriers). Monitoring bone density and being aware of estrogen-deficiency-related symptoms is specifically warranted.

For women undergoing aromatase inhibitor therapy (letrozole, anastrozole), CC carriers start with already-low peripheral estrogen; their symptoms of estrogen deficiency during AI therapy may be more pronounced. Conversely, AA homozygotes (higher aromatase output) may require confirmation that AI therapy is achieving adequate estradiol suppression.

For men with prostate cancer, the C-allele direction (lower aromatase-mediated estrogen synthesis) translates to higher androgen-to-estrogen ratios, which may influence hormone-sensitive tumor biology and response to androgen deprivation therapy.

Interactions

rs727479 sits within a CYP19A1 haplotype block alongside rs4775936 (I.6 promoter variant associated with BMD and AI response), rs2414096 (intron 4 variant associated with PCOS and androgen levels), and rs2414095 (intron 3 variant). These variants are in linkage disequilibrium (r² = 0.10–0.51) and their combined haplotype consistently shows stronger associations than any single SNP alone. In downstream signaling, the estrogen produced by aromatase must bind to estrogen receptors encoded by ESR1 (see related variant rs9340799) — so the combination of altered aromatase output (CYP19A1) and altered receptor sensitivity (ESR1) can amplify or dampen the functional consequences.

Blood pressure is ultimately a plumbing problem: the kidneys decide how much salt to keep and how much to excrete, and that decision sets the volume — and thus the pressure — of your blood. At the center of that decision is WNK1, a serine-threonine kinase expressed throughout the kidney's distal nephron that acts as a master switch for renal salt handling¹¹ WNK1, a serine-threonine kinase expressed throughout the kidney's distal nephron that acts as a master switch for renal salt handling
WNK stands for "with no lysine" — the kinase lacks a conserved lysine residue that most kinases use for catalysis, making it structurally unusual. The rs7305099 variant sits within an intron of WNK1 on chromosome 12, tagging a haplotype block that affects WNK1 expression and activity in the kidney. Its G allele is more common globally and is associated with elevated essential hypertension risk, while the minor T allele is protective.

The Mechanism

WNK1 controls blood pressure by regulating the NaCl cotransporter (NCC)²² NaCl cotransporter (NCC)
NCC is the main sodium-chloride transporter in the distal convoluted tubule of the kidney; its activity directly determines how much sodium is reabsorbed versus excreted in urine in the kidney's distal convoluted tubule. Active WNK1 phosphorylates two intermediate kinases — SPAK and OSR1 — which then phosphorylate and activate NCC, increasing sodium reabsorption. More NCC activity means more salt retained, higher blood volume, and higher blood pressure.

The elegant regulatory feature of this system is its potassium-sensing capacity. When dietary potassium is adequate, intracellular chloride rises in distal tubule cells, directly inhibiting WNK1 kinase activity and allowing more sodium to be excreted. When potassium intake is low, chloride falls, WNK1 activates, NCC is phosphorylated, and sodium retention rises — an evolutionary adaptation to potassium-poor environments that becomes hypertension-promoting in modern high-sodium, low-potassium diets.

A rare but instructive clinical example: large intron 1 deletions in WNK1 that increase WNK1 expression cause Gordon's syndrome (pseudohypoaldosteronism type II)³³ Gordon's syndrome (pseudohypoaldosteronism type II)
characterized by hypertension, high potassium, and metabolic acidosis — a naturally occurring experiment showing what too much WNK1 activity does to blood pressure. The rs7305099 variant is not a deletion, but its haplotype-level effects on WNK1 expression likely operate through the same NCC-mediated mechanism at smaller scale.

The Evidence

The direct association evidence for rs7305099 comes from a case-control study in 476 hypertensive and 491 normotensive Northern Han Chinese participants⁴⁴ case-control study in 476 hypertensive and 491 normotensive Northern Han Chinese participants
Liu et al. 2023, Frontiers in Genetics; 12 WNK1 tag SNPs were tested; rs7305099 survived Bonferroni correction. The T allele was significantly protective against essential hypertension: OR 0.627 (95% CI 0.491–0.801; p<0.0002) in the allele model, with homozygous TT carriers showing strikingly lower risk (OR 0.278, 95% CI 0.140–0.552). This is one population study, so the evidence is moderate rather than strong — but it sits within a well-established biological framework where multiple WNK1 variants across independent cohorts consistently associate with blood pressure variation.

Broader WNK1 variant evidence supports the framework: Newhouse et al. 2009⁵⁵ Newhouse et al. 2009
PLoS One; 1,700 hypertensive cases + 1,700 controls in BRIGHT study, replicated in 17,851 participants across 6 populations showed that the WNK1 intron 1 variant rs765250 (in the same gene region) raises systolic BP by 3.14 mmHg (95% CI 1.23–4.9) — a clinically meaningful effect size for a common variant. Tobin et al. 2005⁶⁶ Tobin et al. 2005 demonstrated that WNK1 haplotypes can shift ambulatory blood pressure by >10 mmHg in some carrier groups, and Tobin et al. 2008⁷⁷ Tobin et al. 2008 followed 5,326 children and found WNK1 variants associate with the rate of diastolic blood pressure increase across childhood — suggesting WNK1 variation shapes the developmental trajectory of blood pressure, not just adult phenotype.

Practical Actions

The WNK1-NCC-blood pressure axis has a well-understood dietary leverage point: potassium intake. Because intracellular chloride (which inhibits WNK1) tracks plasma potassium, adequate dietary potassium directly damps WNK1 activity in the distal nephron. For G allele carriers — especially GG homozygotes — who have higher baseline WNK1-NCC activation, ensuring potassium intake reaches the recommended 3,500–4,700 mg daily from food is the most targeted dietary intervention. This is not generic dietary advice: the mechanism is specific to WNK1 biology and operates differently for people with WNK1 risk variants than for those with normal WNK1 function.

Sodium intake amplifies the risk: the WNK1-NCC system is the molecular substrate of salt-sensitive hypertension. Reducing dietary sodium below 2,300 mg daily reduces NCC substrate availability, partially offsetting higher WNK1-driven transporter activity. Monitoring home blood pressure periodically provides an objective measure of whether the WNK1-related sodium retention is expressing in practice.

Interactions

rs7305099 is one of 12 tag SNPs in WNK1 studied by Liu et al.; it is in the same gene region as rs765250 (intron 1) and rs1012729, though their linkage disequilibrium relationships are not fully characterized across populations. The haplotype A-A-A-C-G-G-G identified in the same study was associated with increased hypertension susceptibility (OR 1.23, p=0.043), suggesting rs7305099 may be part of a broader hypertension-risk haplotype.

WNK1 variants interact biologically with potassium intake (via the chloride-sensing mechanism) and with sodium intake (salt sensitivity). No specific compound genotype interaction with another GeneOps SNP has been published, but the AGT (angiotensinogen) variants rs699 and rs4762, also in the renin-angiotensin system, operate on the same blood pressure output and may compound with WNK1 variation in individuals with multiple risk alleles across these pathways.

The APOL1 gene encodes apolipoprotein L1¹¹ apolipoprotein L1
APOL1 is the human innate immune weapon against African trypanosomes; it forms ion channels in parasite membranes, killing them, a protein best known for its connection to chronic kidney disease in people of African ancestry. Two "risk haplotypes" — G1 and G2 — evolved to fight trypanosome parasites but cause focal segmental glomerulosclerosis (FSGS)²² focal segmental glomerulosclerosis (FSGS)
A kidney disease where the glomeruli — the tiny filtering units — become scarred, leading to protein in the urine and eventual kidney failure and related nephropathies when a person carries two risk alleles. Yet not all G2 carriers develop kidney disease. One key reason: the p.N264K variant (rs73885316, also called M1), a missense change that silences G2's cytotoxicity.

The Mechanism

The G1 and G2 risk variants cause kidney disease by making APOL1 toxic to podocytes³³ podocytes
The highly specialized kidney cells that wrap around glomerular capillaries to form the filtration barrier; podocytes do not regenerate if lost. The variant protein forms aberrant ion channels⁴⁴ ion channels
Pore-like structures that allow sodium, potassium, and calcium ions to flow across cell membranes, disrupting the normal electrochemical balance in podocyte membranes, depleting intracellular potassium and triggering cell death.

The p.N264K substitution — asparagine to lysine at position 264 — sits in the membrane-addressing domain of APOL1, adjacent to the pore-lining segment. In a 2026 structural study⁵⁵ 2026 structural study
Höffken et al. — The APOL1 variant p.N264K is predicted to block ion flow by occluding a pore at the cell surface. Life Sci Alliance, 2026, AlphaFold3 modeling and molecular dynamics simulations showed that the bulkier, positively charged lysine side chain at position 264 physically occludes the ion pore formed by the G2 protein. The M1-G2 protein retains normal cellular localization and surface expression but cannot conduct ions — the pore is blocked.

Critically, N264K and G1 are mutually exclusive⁶⁶ mutually exclusive
Carriers of G1 always have asparagine at position 264; the G1 haplotype physically cannot also carry N264K due to the evolutionary history of these alleles. This means N264K protects only against G2-containing risk genotypes (G1G2 and G2G2), not against G1G1.

The M1 allele likely originated on a non-risk G0 (wild-type) background. A 2025 haplotype study⁷⁷ 2025 haplotype study
Simeone et al. — APOL1 p.N264K is co-inherited with the G2 kidney disease risk variant through a proximity recombination event. G3 (Bethesda), 2025 found that M1 was incorporated into the G2 haplotype through an unusual recombination event within a very short 367-base-pair window between two strong recombination hotspots flanking APOL1 — an evolutionary quirk that created the protective M1-G2 haplotype.

The Evidence

The protective effect of N264K was quantified in a case-control study of 528 FSGS patients and 2,606 genetically matched controls⁸⁸ case-control study of 528 FSGS patients and 2,606 genetically matched controls
Gupta et al. — Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nat Commun, 2023. Among individuals carrying G1G2 genotypes, the presence of N264K reduced the FSGS odds ratio to 0.136 — an 86% risk reduction. For G2G2 homozygotes, the OR was essentially 0, representing near-complete protection. The combined G1G2 + G2G2 group showed an overall OR of 0.08 with N264K present.

A large clinical cohort of 107,696 individuals confirmed these findings in a 2026 JAMA Network Open study⁹⁹ 2026 JAMA Network Open study
Martinelli et al. — Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant. JAMA Netw Open, 2026. M1 was significantly inversely associated with FSGS and steroid-resistant nephrotic syndrome (SRNS) across APOL1 high-risk genotypes (OR 0.20, P = 3.69 × 10⁻³). M1 was four times more frequent in APOL1 high-risk individuals whose CKD had a different cause than in those with FSGS/SRNS, suggesting that M1 carriers with CKD likely have an alternative, potentially treatable underlying cause rather than APOL1-driven disease.

Practical Implications

For individuals of African ancestry who carry two APOL1 risk alleles (particularly G1G2 or G2G2 genotypes), testing for the N264K modifier is clinically important. A G2G2 or G1G2 individual who also carries N264K on the G2 chromosome has markedly lower kidney disease risk than a G2G2 individual without N264K. Conversely, a G1G2 or G2G2 individual without N264K faces substantially elevated risk and warrants active kidney monitoring.

For AC heterozygotes: you carry one copy of the N264K protective allele on one chromosome. If this A allele is co-inherited with a G2 allele on the same chromosome (in cis), it provides protection for that G2 copy. Understanding your full haplotype context — specifically whether the A allele is in cis with G2 — is necessary to interpret your kidney disease risk correctly.

For AA homozygotes (extremely rare in any population): both chromosomes carry the N264K allele. If either chromosome also carries G2, both G2 copies would be protected by the co-inherited N264K.

Interactions

The N264K modifier interacts directly with the APOL1 G2 variant (rs71785313 — the 6-bp deletion removing Asn388 and Tyr389). When N264K is on the same chromosome as G2 (in cis), it abolishes the cytotoxic effect. When N264K is on the opposite chromosome from G2 (in trans), it does not protect the G2 copy.

N264K has no known protective effect against the G1 haplotype variants (rs73885319 S342G and rs60910145 I384M). The G1 and N264K alleles are mutually exclusive — they cannot co-exist on the same chromosome due to their evolutionary history.

For individuals with APOL1 high-risk genotypes involving only G1 (G1G1 homozygotes), N264K status is irrelevant — their kidney risk remains elevated regardless of N264K results.

The LDLR gene¹¹ LDLR gene
encodes the LDL receptor, a cell-surface protein that captures and removes LDL cholesterol from the bloodstream by binding apolipoprotein B-100 on LDL particles and shuttling them into cells for degradation. Without functional LDL receptors, circulating LDL accumulates relentlessly from birth — a condition called familial hypercholesterolemia²² familial hypercholesterolemia
the most common serious monogenic disorder, affecting ~1 in 250 people globally in its heterozygous form.

The rs763625913 variant (c.2308C>T) creates a premature stop codon at position 770 of the LDLR protein, producing a truncated, non-functional receptor. This is a receptor-negative mutation³³ receptor-negative mutation
the receptor is either not made or completely unable to bind LDL, the most severe functional class of LDLR variants. ClinVar classifies it Pathogenic for hypercholesterolemia, familial type 1⁴⁴ hypercholesterolemia, familial type 1
the autosomal dominant form caused by LDLR mutations.

The Mechanism

A nonsense mutation⁵⁵ nonsense mutation
a single DNA base change that replaces an amino acid codon with a stop codon, terminating protein synthesis prematurely at codon 770 (Gln→stop) removes the last 89 amino acids of the mature LDLR protein, which include critical domains required for receptor recycling. The truncated receptor cannot be properly expressed on the hepatocyte surface. With one defective copy (heterozygous state), approximately half the normal number of LDL receptors are present, reducing LDL clearance by ~50% and causing LDL-C to accumulate to 190–300 mg/dL⁶⁶ LDL-C to accumulate to 190–300 mg/dL
roughly 2–3× the normal range from childhood onward. The endogenous cholesterol synthesis pathway⁷⁷ endogenous cholesterol synthesis pathway
the liver continues producing cholesterol but cannot recycle the LDL fraction efficiently through the receptor pathway, compounding the problem.

The Evidence

Pathogenic LDLR nonsense and frameshift variants — the class to which Q770* belongs — are classified as receptor-negative mutations⁸⁸ receptor-negative mutations
producing no functional receptor activity. Bertolini et al. in a multicenter Italian cohort of 282 FH patients⁹⁹ Bertolini et al. in a multicenter Italian cohort of 282 FH patients
clustering mutations by regional ancestry and functional class showed that receptor-negative carriers had 18% higher LDL-C, 2.6-fold more coronary artery disease, and 2-fold more tendon xanthomas than receptor-defective carriers — confirming that complete receptor abolition is the most severe functional consequence of LDLR mutation.

Without treatment, untreated heterozygous FH carries approximately 50% cumulative coronary event risk by age 50 in men and 30% by age 60 in women¹⁰¹⁰ 50% cumulative coronary event risk by age 50 in men and 30% by age 60 in women
based on natural history registry data from the pre-statin era. The overall coronary disease excess is estimated at up to 13-fold compared to the general population¹¹¹¹ up to 13-fold compared to the general population
European Atherosclerosis Society consensus statement on FH. Critically, this risk is dramatically modifiable: high-intensity statin therapy initiated early reduces cardiovascular events by 50–80% and narrows the life expectancy gap with unaffected relatives.

This variant is extremely rare (one observation across 595,462 gnomAD exome alleles), consistent with strong purifying selection — individuals carrying it face severely elevated cardiovascular risk from birth, and reproductive fitness is reduced. Most carriers identified in clinical practice are ascertained through cascade screening after a proband is diagnosed with premature CAD or markedly elevated LDL-C.

Practical Actions

Carrying this variant is a medical diagnosis equivalent to clinically confirmed FH. The first priority is confirming the lipid phenotype with a fasting lipid panel — LDL-C is typically 190–300 mg/dL in untreated heterozygotes. High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) should be initiated regardless of age in adults, and as early as age 8–10 in affected children. The LDL-C target is <100 mg/dL for most carriers, or <70 mg/dL if coronary artery disease is already present. Because receptor-negative variants produce a more severe phenotype than receptor-defective variants, reaching these targets often requires combination therapy: high-intensity statin + ezetimibe 10 mg, and frequently a PCSK9 inhibitor¹²¹² PCSK9 inhibitor
evolocumab or alirocumab, which increase LDL receptor expression from the remaining functional allele by preventing receptor degradation.

Because FH follows autosomal dominant inheritance, every first-degree relative has a 50% chance of carrying this variant. Cascade genetic testing or LDL-C screening in parents, siblings, and children is recommended as soon as the proband is identified — early intervention in childhood prevents decades of LDL-C-driven atherosclerosis.

Interactions

This variant interacts with other cholesterol pathway variants. Carriers who also carry a PCSK9 gain-of-function variant¹³¹³ PCSK9 gain-of-function variant
e.g. rs28942080 D374Y face compounded LDL receptor dysfunction: PCSK9 rapidly degrades the residual functional LDLR protein, making pharmacologic PCSK9 inhibition especially important. Conversely, carriers of PCSK9 loss-of-function variants¹⁴¹⁴ PCSK9 loss-of-function variants
such as rs28362261 Y142X may show attenuated LDL elevation even with one defective LDLR allele, because more of the functional receptor is preserved.

Lifestyle factors modify penetrance: obesity, insulin resistance, and hypothyroidism all further impair LDL clearance and worsen the phenotype, while intensive dietary fat restriction (saturated fat below 7% of calories) can modestly reduce LDL-C by 10–15% on top of pharmacotherapy. These lifestyle modifications do not substitute for statins in this context but can assist in reaching LDL targets.

HLA-DPB1 encodes the beta chain of the HLA-DP molecule, a class II MHC receptor that presents peptide antigens to CD4+ T helper cells. This is the essential handshake that triggers adaptive immunity: without robust HLA-DP surface expression, the immune system cannot efficiently recognize viral peptides and mount a clearance response. The rs9277535 variant sits in the [3' untranslated region (3' UTR) | The regulatory sequence at the end of the mRNA transcript that controls stability, translation efficiency, and expression level — not the protein-coding region itself] of HLA-DPB1 and acts as an [eQTL | expression quantitative trait locus — a variant whose primary effect is on how much gene product is made rather than what kind] controlling transcript levels. The G allele substantially reduces HLA-DPB1 mRNA, shifting the antigen presentation dial downward.

The Mechanism

The rs9277535 G allele lies in the 3' UTR of HLA-DPB1 transcript NM_002121.6 and is in [linkage disequilibrium | Alleles at nearby positions that tend to be inherited together more often than expected by chance, so rs9277535 G tags a broader haplotype block] with functionally connected variants across the HLA-DP locus. Expression studies confirmed that the GG genotype is associated with the lowest HLA-DPB1 mRNA levels¹¹ GG genotype is associated with the lowest HLA-DPB1 mRNA levels
p=10⁻¹⁵ in 651 normal liver samples; allelic expression imbalance analysis in 17–19 heterozygotes confirmed the G allele produces less transcript than the A allele across liver tissue. Lower surface HLA-DPB1 expression translates directly to fewer antigen-presenting molecules available to engage virus-derived peptides and activate CD4+ T helper cells.

The consequence is a classic MHC trade-off: reduced HLA-DPB1 expression limits the risk of excessive immune activation (relevant to autoimmune conditions), but also limits the immune system's capacity to clear intracellular pathogens that depend on CD4+ T helper responses for viral elimination. This tension explains why rs9277535 simultaneously influences risk in opposite directions for viral infections and certain autoimmune diseases.

The Evidence

Hepatitis B clearance provides the most robustly replicated phenotype. A study of 200 Taiwanese chronic HBV patients compared those who spontaneously [cleared HBsAg | Hepatitis B surface antigen — its disappearance from blood marks functional cure of chronic infection] against persistent carriers, finding the non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)²² non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)
Cheng et al. 2013, PLoS One; haplotype analysis combining rs3077 and rs9277535 strengthened the OR to 2.17. Replication in an Indonesian cohort of 686 participants confirmed a protective association across a South-East Asian population (OR 0.70 additive model, P=0.026)³³ (OR 0.70 additive model, P=0.026). The underlying molecular mechanism — reduced HLA-DPB1 expression in risk allele carriers — was mechanistically established in liver eQTL analysis, directly linking the expression deficit to the antigen presentation failure that allows HBV to persist (O'Brien et al. 2011, Genes & Immunity)⁴⁴ (O'Brien et al. 2011, Genes & Immunity).

Autoimmune disease associations reveal the other side of the trade-off. In multiple sclerosis, rs9277535 shows an independent genome-wide significant association with susceptibility (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls)⁵⁵ (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls) driven by the correlation with HLA-DPB1*03:01 — a specific protein allotype linked to MS in earlier candidate-gene studies. For rheumatoid arthritis, the picture reflects the expression axis clearly: in Chinese Han patients, the A allele (higher HLA-DPB1 expression) was associated with increased RA susceptibility (OR 1.409, P=0.004; 254 RA cases, 391 controls)⁶⁶ (OR 1.409, P=0.004; 254 RA cases, 391 controls) and elevated anti-CCP antibodies, while the G allele (lower expression) was protective⁷⁷ G allele (lower expression) was protective
OR for protective effect confirmed in 805 RA patients vs 1,095 controls; AG and GG genotypes associated with lower plasma HLA-DPB1 levels. This inverse relationship — the same allele that reduces HBV clearance reduces RA risk — is the hallmark of [balancing selection | Evolutionary pressure maintaining both alleles in a population because heterozygotes have an advantage over either homozygote, common in MHC genes exposed to conflicting infectious and autoimmune pressures] at the MHC locus.

Practical Actions

The G allele's primary actionable consequence is impaired HBV clearance capacity. GG homozygotes have lower HLA-DPB1 surface expression, producing a weaker CD4+ T helper response to hepatitis B antigens. This translates to reduced natural clearance after HBV exposure and, importantly, reduced vaccine response — HBV vaccine efficacy depends on the same antigen presentation machinery this variant diminishes. AA individuals who carry two copies of the higher-expression A allele have efficient antigen presentation but carry elevated susceptibility to autoimmune conditions like RA in populations where this trade-off is clinically relevant.

The G allele is substantially more common in East Asian populations (~62% allele frequency vs ~24% in Europeans), which aligns with the higher burden of HBV chronic infection in East Asian countries and the known population-stratified effects of HLA-DP variants on HBV outcomes. Because G allele carriers may mount suboptimal vaccine responses, verifying seroconversion after HBV vaccination is a specific, genotype-informed recommendation.

Interactions

rs9277535 interacts with rs3077 (in the 3' UTR of the neighboring HLA-DPA1 gene) to form a combined HLA-DP haplotype. The GA haplotype (rs3077 G + rs9277535 A) showed a stronger association with HBV clearance than either SNP alone (OR 2.17 vs 1.83 for rs9277535 alone). The two SNPs co-regulate the HLA-DPA1/DPB1 heterodimer — the functional antigen presentation unit — meaning that variation in both alpha and beta chains together determines the overall antigen presentation phenotype. The nearby rs9277534 (496A/G) tags a different haplotype block with partially overlapping effects. For a comprehensive HLA-DP antigen presentation assessment, both rs3077 and rs9277535 should be interpreted together.